Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy
Metrics: PDF 458 views | ?
1 University of Torino School of Medicine, Candiolo Cancer Institute-FPO, IRCCS, Str. Provinciale, Candiolo, Torino, Italy
2 Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo,Palermo, Italy
3 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
4 Molecular Biotechnology Center (MBC), Department of Oncological Sciences, Center for Molecular Systems Biology, Via Nizza, University of Torino, Torino, Italy
Published: August 13, 2019
This article has been corrected: Due to errors in image assembly, the flow cytometry profiles depicting the isotype matched control (IMC) for CD49f on both scramble (scr) and miR-100 reported in Figure 6 are incorrect. Additionally, we noticed that the IMC reported for CD24 and CD10 in miR-100 are the same. Being both CD24 allophycocianin (APC) and CD10 APC IgG1, they should have the same IMC, as already reported. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
Original article: Oncotarget. 2015; 6:2315–2330. DOI: https://doi.org/10.18632/oncotarget.2962.
Figure 6: Ectopic expression of miR-100 reduces stem cell markers and induces markers of differentiation. Flow cytometry analysis of CD44, CD24, CD10, CD49f and EpCAM expression in BrCSCs (P5) scramble and stably expressing miR-100. IMC: Isotype Matched Control.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.